English (UK)
中文版HungaroTrial CRO 
To Overachieve, your clinical trial needs the best minds from beginning to end. That’s why Hungarotrial’s full-time staff includes 12 MDs of various specialties,more than any other independent CRO in the region. And you can be assured that our experienced team has built strong relationships with the most respected Key Opinion Leaders in CEE.
Our staff’s broad medical experience means that your clinical study benefits from diverse skills and synergistic teamwork. Over the past 18 years, HungaroTrial has become well known not just for this broad expertise, but also for our deep experience in Oncology, Rheumatology, Cardiovascular diseases, PAO, CNS and some other focus therapeutic areas.
Matteo Manco
BDD
i3 Consult 
Wallace Macindoe
CEO & FounderIHM-GBA 
Based in Guanghzou, China, IHM-GBA is an innovation center focusing on high performance medical device. We are seeking global opportunities of bringing disruptive technologies to the Chinese market. We invest in and partner with startups that are interested in exploring China and use our resources to commercialize their products.
Mr shu zeng
DirectorImmunoBiochem 
Anton Neschadim
DirectorINOVOTION
Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage.
This breaking-thought technology, based on chick embryo, provides early analysis of your anti-cancer treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs.
It’s rapid Go/No Go decision with multi-cancer screening capacities.
This next generation of in vivo efficacy and toxicity tests covers fours main aspects:
- EFFICACY assays for your treatments in oncology and immuno-oncology
- EARLY TOXICITY assays for your drug candidates
- TARGET VALIDATION in oncology
- MULTI-CANCER SCREENING to (re)positioning your treatment
Philippe Fornies
Head of Business DevelopmentInvivoSciences Inc. 
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.
Ayla Annac
CEOIsrael Foreign Trade Administration
Kathy Tong
Trade Director
Kymeris Therapeutics Inc.
Kymeris Therapeutics (Canada) has exlusive license to a ground-breaking cell-based immunotherapeutic product for clinical development in cancer. This multivalent anti-cancer platform integrates multiple mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses encoded biodrugs in the cancer - but not systemically.
* We are seeking partners with small molecule or antibody (or any encodable peptide or protein) that would have an enabling platform compared to intravenous or intratumoral formulations.
* We are also seeking strategic investors in the platform that has extremely high potential in future products, adaptable against almost any solid cancer.
------------------------------------------------------------------
The platform can enable, or enhance, additional small molecule, antibody, peptide or cytokine agents. It is a preclinical late-stage firm that has discovered and developed a First-in-Class immunotherapeutic platform based on non-pathogenic eukaryotes (nucleated cells, non-viral, non-bacterial). Our platform is original with the first scientific paper just published in November 2020 by the Journal of Immunotherapy of Cancer (BMJ), and our first scientific presentation at the 2020 Annual Meeting of the SITC where we presented recent report on a derivative that secreted human IL-15 within tumor, but devoid of serum detection of the cytokine.
The platform would be a paradigm shift from "reductive" (targeted, mono-mechanism) approaches, and can be encoded with additional molecular therapies to more comprehensively face the complex of solid cancer defenses. Encoding any biological agent (small molecule, antibody, antigen, cytokine...), could enable that agent for a wider scope of applications, enhanced effect and much safer profile. In addition, the platform shows abscopal effect, an ability to reach tumors after administration from a distance (subcutaneous or mucosal).
The platform has shown the following characteristics:
1. Tumor-tropism / Cancer-agnostic. Homing to tumor occurred in the absence of a cancer antigen marker (TAA or TSA), and may even work in tumors that are not easily "targetable", such as "cold", lacking cancer markers, heterogeneic or mutating tumors. One oncologist remarked, "This turns "cold" tumors "hot" ".The agents have had effect at distance from tumor site when administered subcutaneously or mucosally.
2. Tumor-infiltration + TME counteraction. The agents bear a specialized "universal key" to gain entry into mammalian cell in an active process; no specific receptor needed. In addition, the agents are able to reprogram tolerogenic cells into a state of immune competence i.e. to overcome cancer-induced immune suppression within the tumor.
3. Intra-cancer delivery of any payload/s. Obligate intracellular microbes, the agents infect cancer cells and replicate, expressing encoded biodrugs. The replication continues as long as there is cancer tissue to infect and/or the TME has not been disabled. Any agents outside of the TME were naturally cleared in under 10 days.
Responsive Web Design powered by 